Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Phase 2 Recruiting 35 enrolled The First Affiliated Hospital of Soochow University

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of Genetic subtype-matched targeted therapy in the treatment of treatment-naive diffuse large B-cell lymphoma with TP53 mutation.

Timeline

Start: 2026-01-01
Primary completion: 2027-12-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	25 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Subject	Orelabrutinib	Small molecule	150 mg	Oral
Subject	Polatuzumab Vedotin	Other / unclassified	1.8 mg/kg	Intravenous
Subject	Prednisone	Other / unclassified	100 mg	—
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Summary

Timeline

Drugs

Indications